Thynk Capital
Venture capitalPre-Seed–Series A · 1 people tracked
Investment thesis
Thynk Capital focuses on early-stage therapeutics, healthcare, and technology companies, supplying growth capital and value-added resources to optimize performance and increase enterprise value while targeting above-market returns for limited partners. The firm works closely with portfolio companies to improve operational efficiency, strengthen management teams, and build strategic growth roadmaps. It is expanding into early-stage pharma and biotech focused on extending healthspan and addressing major diseases of aging such as Alzheimer's, dementia, kidney disease, cancer, cardiovascular disease, diabetes, frailty, and rare disease. The firm also emphasizes accelerating cutting-edge technology and building a platform of innovation.
Source: firm website, verified Aug 3, 2026.
Team · 1 people
from the firm's website
What they invest in
from 13 of 17 portfolio companiesBiotech ×10Medical Devices ×5Healthtech ×4Digital Health ×2Longevity ×2SaaS ×2Construction Tech ×1Deep Tech ×1
HQs:United States×9
Investments · 17 tracked
founders shown can be your intro pathBy year:2020 · 12017 · 12015 · 13 dated
Encinitas, US
Edward White(Executive Officer)Charles H. Silver(Executive Officer, Director)Edgar F. Berner(Director)Craig S. Andrews(Director)David L.R. Stein(Executive Officer)Steven D. Sprenger(Director)
PartnerJim Plante· solo GP
Curtana Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule inhibitors for brain cancer, particularly pediatric high-grade glioma.
BiotechMedical DevicesAustin, US
PartnerJim Plante· solo GP
E-Band designs and manufactures millimeter-wave wireless systems for 5G networks and ultra-low-latency applications such as high-frequency trading, multimedia, and gaming.
Hardware
PartnerJim Plante· solo GP
Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation.
BiotechHealthtechLongevityMenlo Park, US
Mark Allen(Executive Officer, Director)Casey J McGlynn(Executive Officer)Sebastian Giwa(Executive Officer, Director)Luis Alvarez(Executive Officer)Daniel Marshak(Director)
BoardSuzanne Fletcher(Director)
PartnerJim Plante· solo GP
Co-investorsBold Capital PartnersBOLD CapitalFor Good VenturesLauder PartnersPrime Movers LabWTI
Manhattan Beach, US
Geeta Gupta(Executive Officer, Director, Promoter)Henrik Fisker(Executive Officer, Director, Promoter)William R. McDermott(Director)Mark Hickson(Director)Roderick K. Randall(Director)
BoardNadine Watt(Director)
PartnerJim Plante· solo GP
Co-investorsCapital Q® Ventures Inc.
Geospan provides software tools (gSquare and gPro) that generate 99% accurate 3D roof measurements and estimates using aerial photography and patented technology for construction, insurance, real estate, and public security professionals.
Construction TechPropTechSaaS
PartnerJim Plante· solo GP
PartnerJim Plante· solo GP
IVIVA Medical develops fully implantable bioartificial kidneys as a potential cure for patients with chronic kidney disease, diabetes, and kidney failure.
BiotechHealthtechMedical Devices
PartnerJim Plante· solo GP
Co-investorsBold Capital PartnersPrime Movers Lab
Mercer Island, US
Ronald Berenson(Executive Officer, Director, Promoter)
PartnerJim Plante· solo GP
Co-investorsElevate CapitalPallasite Ventures
Klotho Therapeutics uses biotechnology to develop therapeutics that mimic the natural human Klotho protein to address age-related diseases including cognitive decline, kidney failure, diabetes, and cancer.
BiotechLongevity
PartnerJim Plante· solo GP
Lübris BioPharma develops recombinant human lubricin for treating dry eye, osteoarthritis, and age/inflammation-related conditions.
BiotechHealthtechMedical Devices
PartnerJim Plante· solo GP
Co-investorsTarnagulla Ventures
BiotechSyracuse, US
Guilherme Cherman Perdigao de Oliveira(Executive Officer, Director)Reason("CEO's full legal name is ""Reason""")Anthony Matthew Chow(Director)
BoardKelsey Moody(Director)
PartnerJim Plante· solo GP
Co-investorsquadraScope Venture Fund
SmartDrive Systems provides video-based fleet safety and analytics solutions for commercial transportation companies, including trucking fleets and transit systems, to prevent collisions and improve driver performance.
Enterprise SoftwareIoTLogistics & Supply ChainSaaS
PartnerJim Plante· solo GP
Co-investorsNewView CapitalOak Investment PartnersSixth Street
Theragene Pharmaceuticals develops immunotherapy and gene therapy treatments for cancer and cardiovascular diseases using AAV technology.
BiotechDigital HealthMedical DevicesSan Diego, US
Jon Berglin(Executive Officer, Director)
BoardSteven Davis(Director)Daniel Coury(Director)Chaojie Zhang(Director)
PartnerJim Plante· solo GP
Viscient develops 3D human tissue models for drug development, replacing animal models in preclinical and clinical testing.
BiotechDeep TechDigital Health
PartnerJim Plante· solo GP
BiotechSan Diego, US
Stan Kim(Executive Officer, Director)Nigel Calcutt(Director)
PartnerJim Plante· solo GP
X4 Pharmaceuticals develops and commercializes therapies for rare immune system diseases, including XOLREMDI (mavorixafor), which received U.S. approval, and is running a Phase 3 trial in chronic neutropenic disorders.
BiotechHealthtechMedical DevicesBoston, US
PartnerJim Plante· solo GP
Co-investorsLumira VenturesPartners Resolute
Portfolio news
latest coverage across their companiesElevian · nasdaqprivatemarket.com · Jun 27, 2025
Frequently asked questions
- How many investments has Thynk Capital made?
- Thynk Capital has 17 tracked investments.
- What stage does Thynk Capital invest at?
- Thynk Capital invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Thynk Capital focus on?
- Thynk Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Who does Thynk Capital co-invest with?
- Thynk Capital most often shares deals with Bold Capital Partners, Lumira Ventures, NewView Capital, among 12 tracked co-investors.
Similar investors
Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Snatched Ventures is a San Francisco-based early-stage venture capital firm backing DeepTech startups focused on sustainable innovation and operational transformation. It is led by a two-GP team combining corporate development and institutional investment management experience.
Overwater Ventures is an early-stage venture firm that partners with pre-seed and seed stage founders working on large-scale problems, offering hands-on support across launch strategy, go-to-market, fundraising, and marketing.